Jia Dan

Jia Dan

Auto-generated profile, based on publicly available information

Jia Dan

Organ Transplant Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
QZQiang Zhao
Qiang Zhao
XWXiaobo Wang
Xiaobo Wang
KLKunpeng Liu
Kunpeng Liu
HCHonghui Chen
Honghui Chen
JDJia Dan
Jia Dan
XHXiaoshun He
Xiaoshun He
The shortage of transplant organs remains a severe global issue. Normothermic machine perfusion (NMP) has the potential to increase organ availability, yet its efficacy is hampered by the inflammatory response during machine perfusion. Mouse liver IRI models, discarded human liver models, and porcine marginal liver transplantation models were utilized to investigate whether FXR activation could mitigate inflammation-induced liver damage. FXR expression levels before and after reperfusion were measured. Gene editing and co-immunoprecipitation techniques were employed to explore the regulatory mechanism of FXR in inflammation inhibition. The expression of FXR correlates with the extent of liver damage after reperfusion. Activation of FXR significantly suppressed the inflammatory response triggered by IRI, diminished the release of pro-inflammatory cytokines, and improve liver function recovery during NMP, assisting discarded human livers to reach transplant standards. Mechanistically, FXR disrupts the interaction between p65 and p300, thus inhibiting modulating the nuclear factor kappa-B (NF-κB) signaling pathway, a key instigator of inflammation. Our research across multiple species confirms that activating FXR can optimize NMP by attenuating IRI-related liver damage, thereby improving the utilization of marginal livers for transplantation.

15 August 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
Purpose: This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)–T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV–hepatocellular carcinoma after liver transplantation. Patients and Methods: In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV–TCR–T cells (mRNA–HBV–TCR–T cells) and (ii) one to three infusions of lentiviral-transduced HBV–TCR–T cells (lenti-HBV–TCR–T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor efficacy was evaluated using CT imaging according to RECIST v1.1 criteria. Progression-free survival (PFS) was defined as the time from the start of study treatment until objective tumor progression or death. Results: Both mRNA-electroporated and lentiviral-transduced HBV-specific TCR–T cells demonstrated a favorable safety profile, with only grade 1 to 2 treatment-related adverse events observed. In the mRNA–HBV–TCR–T cells cohort, the median PFS was 2.32 months (range, 1.87–2.77 months). The combination therapy cohort (mRNA–HBV–TCR–T cells + lenti-HBV–TCR–T cells) showed a median PFS of 7.34 months (range, 4.47–7.60 months). CT imaging indicated effective tumor control in the combination therapy group. Conclusions: This study preliminarily suggests that the combination of mRNA–HBV–TCR–T cells and lenti-HBV–TCR–T cells could be a safe and potentially effective approach for treating patients following liver transplantation in the context of lifelong immunosuppression drug administration. Further studies are needed to refine treatment strategies and assess long-term safety and efficacy in this special patient population.


15 September 2025
Verified
Other
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
Figure S2 from HBV-Specific TCR–T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation

15 September 2025
Verified
Other
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
A–F, Changes in inflammatory cytokine levels at different time points during the HBV–TCR–T cell treatment. MIG, monokine induced by gamma interferon.

15 September 2025
Verified
Other
Open access
QZQiang Zhao
Qiang Zhao
JHJinbo Huang
Jinbo Huang
WLWeixin Luo
Weixin Luo
HTHaidong Tan
Haidong Tan
RWRegina Wan Ju Wong
Regina Wan Ju Wong
XHXiaoshun He
Xiaoshun He
A–F, Activity of HBV–TCR–T cells in peripheral blood at various time points. The black vertical dashed lines indicate the infusion time points for mRNA–HBV–TCR–T cells, and the red vertical dashed lines indicate the infusion time points of lenti-HBV–TCR–T cells.